Skip to main content
OpenTrials
Completed

NCT Number: NCT05647824

User Performance of the TV4 BGMS

Thunder V4 (TV4) is the code name of a blood glucose monitoring system (BGMS) consisting of a new meter and new Contour FIT test strips. This clinical trial will assess the performance (accuracy) of the TV4 meter by lay users enrolled as subjects in the study, and by health care professionals (also called study staff).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Diablo Clinical Research (DCR), Walnut Creek, California, United States

Loading trial locations.

About this study

The study will be conducted at three clinical sites and enroll a total of approximately 402 lay users. Ten to fifteen percent (10 - 15%) of the enrolled subjects will be naïve users (naïve to SMBG's and may include people without diabetes). At least twenty percent (20%) of subjects enrolled with diabetes will have Type 1 diabetes. At least 70% of subjects will be younger than age 65. Sites will also enroll subjects of Chinese descent.

This clinical investigation will be conducted within the US.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males and females, 18 years of age and older
  • Ability to speak, read and understand English. Subjects must demonstrate the ability to read a paragraph from the first page of the User Guide (UG) to qualify for the study.
  • Willing to complete all study procedures

Exclusion criteria

  • Subjects without diabetes that are not naïve to Blood Glucose Monitoring System.
  • Hemophilia or any other bleeding disorder
  • Pregnancy (self-reported)
  • Physical, visual or neurological impairments that would make the person unable to perform testing with the BGMS.
  • Previous use of the Ascensia Contour Thunder V3 (TV3), or Thunder PLUS (T-PLUS), or Thunder V4 (TV4) BGMS.
  • Working for a medical laboratory, hospital or another clinical setting that involves training on, or clinical use of blood glucose monitors.
  • Being in this trial during or soon after xylose absorption testing (Xylose in the blood is known to cause interference). However, subjects can be enrolled as soon as 2 days after the test is performed (25 gms of oral xylose administered during this test is cleared within 480 mins or 8 hours).
  • A condition, which in the opinion of the investigator or designee, would put the person or study conduct at risk. The reason for exclusion will be clearly documented by investigator or designee on the subject disposition form.
  • Working for a competitive medical device company, or having an immediate family member or someone who is not a family member but is living within the household of someone who works for such a company.
  • Immediate family members are the subject's parents, spouse, children, and siblings, including the parent's spouse; step-children and adopted children and their spouses.
  • A competitive medical device company is a company that provides a medical device or components of a device that is related to diabetes.

For example, people who are not eligible are those who work for companies that create or manufacture the following (or a company that is in a partnership with a company that provides such devices): lancing devices, blood glucose monitoring systems, continuous glucose monitoring systems, insulin pens, or systems related to the measurement of HbA1c.

People who are eligible are those who work for companies associated with products such as wound dressings, medications or dietary products.

Treatment and study plan

Capillary Testing

Device

Testing Contour Fit BGMS with capillary blood

Other names: Contour Fit BGMS

Alternative Site Testing (AST)

Device

Testing Contour Fit BGMS using blood from alternative site

Other names: Contour Fit BGMS

Venous Testing

Device

Testing Contour Fit BGMS with venous blood

Other names: Contour Fit BGMS

Primary outcomes

  1. Fingerstick Test: Obtain TV4 BGMS performance data in the hands of lay users with diabetes using fingerstick capillary blood obtained with Microlet NEXT® lancing device.

    Time frame: 4 weeks

    Number of glucose results falling within ±15mg/dL of laboratory method at glucose concentration <100 mg/dL and within ±15% at glucose concentrations ≥100 mg/dL

Secondary outcomes

  1. Alternative Site Test (AST): Obtain TV4 BGMS performance data in the hands of lay users with diabetes using capillary blood from the palm site obtained with Microlet NEXT lancing device with the AST endcap.

    Time frame: 4 weeks

    Number of glucose results falling within ±15mg/dL of laboratory method at glucose concentration <100 mg/dL and within ±15% at glucose concentrations ≥100 mg/dL

  2. Venous Blood Test: Obtain TV4 BGMS performance data using venous blood from lay users with diabetes.

    Time frame: 4 weeks

    Number of glucose results falling within ±15mg/dL of laboratory method at glucose concentration <100 mg/dL and within ±15% at glucose concentrations ≥100 mg/dL

  3. Subject Questionnaire on the Usability of TV4 BGMS

    Time frame: 4 weeks

    Number of results with scores of 3 or higher to statements concerning instructions for use or ease of use. Scores of 3 or greater (on a scale of 0 to 5) are more favorable to usability.

Sponsors and collaborators

Lead sponsor

Ascensia Diabetes Care

Industry

Registry information

Official study title

User Performance of the TV4 Blood Glucose Monitoring System

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Dec 13, 2022
Registry last updated
Feb 2, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.